Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Disease

Objective To evaluate the effect of finasteride on serum androst-4-ene-3,17-dione (androstenedione) and its association with prostate cancer risk among subjects who participated in the Prostate Cancer Prevention Trial. Methods We analyzed serum androstenedione levels in 317 prostate cancer cases and...

Full description

Saved in:
Bibliographic Details
Published in:Urology (Ridgewood, N.J.) N.J.), 2015-03, Vol.85 (3), p.616-620
Main Authors: Hoque, Ashraful, Yao, Song, Till, Cathee, Kristal, Alan R, Goodman, Phyllis J, Hsing, Ann W, Tangen, Catherine M, Platz, Elizabeth A, Stanczyk, Frank Z, Reichardt, Juergen K.V, vanBokhoven, Adrie, Neuhouser, Marian L, Santella, Regina M, Figg, William D, Price, Douglas K, Parnes, Howard L, Lippman, Scott M, Ambrosone, Christine B, Thompson, Ian M
Format: Article
Language:English
Subjects:
Androstenedione - blood
Case-Control Studies
Double-Blind Method
Finasteride - pharmacology
Finasteride - therapeutic use
Humans
Male
Middle Aged
Neoplasm Grading
Prostatic Neoplasms - epidemiology
Prostatic Neoplasms - pathology
Prostatic Neoplasms - prevention & control
Risk Assessment
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate the effect of finasteride on serum androst-4-ene-3,17-dione (androstenedione) and its association with prostate cancer risk among subjects who participated in the Prostate Cancer Prevention Trial. Methods We analyzed serum androstenedione levels in 317 prostate cancer cases and 353 controls, nested in the Prostate Cancer Prevention Trial, a randomized placebo-controlled trial that found finasteride decreased prostate cancer risk. Androstenedione is the second most important circulating androgen in men besides testosterone and also a substrate for 5α-reductase enzyme. Results We observed a 22% increase in androstenedione levels compared with the baseline values in subjects who were treated with finasteride for 3 years. This significant increase did not vary by case-control status. Adjusted odds ratio and 95% confidence interval for the third tertile of absolute change in androstenedione levels compared with the first tertile were 0.42 (95% confidence interval, 0.19-0.94) for low-grade (Gleason score 
ISSN:0090-4295
1527-9995
DOI:10.1016/j.urology.2014.11.024